Physician profile
Allison Hinds
NPI 1538376801
$2,907.95
in general payments reported to CMS, 2019-2025
10 companies · $1,139 in 2025
The $1,139 reported for 2025 was more than what 83% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $110 · 2021: $125 · 2022: $13.58 · 2023: $620 · 2024: $901 · 2025: $1,139.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,659.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,659.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $666.27 | 2022-2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $497.99 | 2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $407.69 | 2021-2025 | Invega Sustenna, Spravato |
| Teva Pharmaceuticals USA, INC. | $247.09 | 2023 | Uzedy |
| Otsuka America Pharmaceutical, INC. | $244.90 | 2024-2025 | Abilify Maintena, Abilify Asimtufii |
| Idorsia Pharmaceuticals US INC | $244.86 | 2023-2024 | Quviviq |
| Alkermes, INC. | $239.19 | 2024-2025 | Vivitrol |
| Vanda Pharmaceuticals INC. | $125.00 | 2024 | Fanapt |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $125.00 | 2024 | |
| Eisai INC. | $109.96 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allison Hinds listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.